Latest from Joseph Haas
Novartis will also pay up to $1.9bn for milestones and share US profits on the Phase II RNA-splicing candidate. PTC is discussing potential accelerated approval with the US FDA.
Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.
Plus deals involving Novartis with Vyriad, Ratio and Schrödinger; Pharmanovia/Lindis, Pulmatrix/Cullgen, Entero/Journey, Roche/Flare and AlloVir/Kalaris.
Plus deals involving Zai Lab/Pfizer, Laekna/Lilly, Takeda/Alloy, Lunit/AstraZeneca, VelaVigo/Avenzo, Biosion/Aclaris, HCW/WY Biotech, Celltrion/iQone and Kaken/Numab.
Boston Pharma may be rising in the FGF21 space, while Viking could be formidable competition for Madrigal in the THRβ agonist class. Akero will soon report potentially groundbreaking data in cirrhotic NASH.
The firm revealed that an analysis of its Phase III ESSENCE trial combining fibrosis reduction and NASH resolution showed a higher effect over placebo than in Madrigal’s pivotal trial.